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Usp9X Regulates Cell Death in 
Malignant Peripheral Nerve Sheath 
Tumors
E. Bianchetti1, S. J. Bates1, S. L. Carroll2, M. D. Siegelin1 & K. A. Roth  1
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in 
neurofibromatosis type 1 (NF1) patients. Current treatment modalities have been largely unsuccessful 
in improving MPNST patient survival, making the identification of new therapeutic targets urgent. In 
this study, we found that interference with Usp9X, a deubiquitinating enzyme which is overexpressed 
in nervous system tumors, or Mcl-1, an anti-apoptotic member of the Bcl-2 family whose degradation 
is regulated by Usp9X, causes rapid death in human MPNST cell lines. Although both Usp9X and Mcl-1 
knockdown elicited some features of apoptosis, broad spectrum caspase inhibition was ineffective 
in preventing knockdown-induced MPNST cell death suggesting that caspase-independent death 
pathways were also activated. Ultrastructural examination of MPNST cells following either Usp9X 
interference or pharmacological inhibition showed extensive cytoplasmic vacuolization and swelling of 
endoplasmic reticulum (ER) and mitochondria most consistent with paraptotic cell death. Finally, the 
Usp9X pharmacological inhibitor WP1130 significantly reduced human MPNST growth and induced 
tumor cell death in an in vivo xenograft model. In total, these findings indicate that Usp9X and Mcl-1 
play significant roles in maintaining human MPNST cell viability and that pharmacological inhibition of 
Usp9X deubiquitinase activity could be a therapeutic target for MPNST treatment.
Neurofibromatosis type 1 (NF1) is a genetic neurocutaneous disease with an incidence of 1:30001,2 characterized 
by a predisposition to multiple peripheral nerve sheath tumors3. The vast majority of NF1-associated nerve sheath 
tumors are benign, but malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in 
NF1 patients. MPNSTs are aggressive Schwann cell-derived soft tissue sarcomas and occur in 5 to 10% of patients 
with NF14. Approximately half of MPNSTs are associated with NF1 and often arise from benign plexiform neu-
rofibromas5. Currently, standard MPNST therapy is tumor resection with wide surgical margins, but patient 
prognosis is poor due to variables such as tumor size, anatomic location, propensity to metastasis and limited 
tumor cell sensitivity to chemotherapy and radiation1. Therefore, identification of new therapeutic targets to treat 
this aggressive neoplasm is a high clinical priority.
Usp9X is a deubiquitinating enzyme which is overexpressed in various human cancers, including nervous sys-
tem tumors, such as glioblastoma (GBM)6. Genetic and/or pharmacological inhibition of Usp9X activity has been 
shown to induce tumor cell death in both in vitro and in vivo models of GBM6–8. Previous studies have demon-
strated that down-regulation of Usp9X is followed by enhanced degradation of the anti-apoptotic Bcl-2 family 
member, myeloid cell leukemia 1 (Mcl-1)7,9. Furthermore, Mcl-1 down-regulation is known to be an important 
determinant of apoptosis in sarcomas10. Our findings suggest that Usp9X and Mcl-1 are novel targets for the 
treatment of MPNSTs and that paraptosis, a caspase-independent type of regulated cell death, may play a role in 
MPNST cell death induced by Usp9X inhibition.
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Results
Usp9x is expressed in human MPNST cell lines. Usp9X expression in MPNSTs has not previously been 
reported. Thus to ensure potential human clinical relevance, we first examined Usp9X expression levels in a panel 
of human MPNST cell lines (Suppl. Figure 1a). All MPNST cells showed Usp9X protein expression, albeit at dif-
ferent levels. The results confirm that the Usp9X protein is expressed in MPNST cells, reinforcing the notion that 
Usp9X is a viable, potential therapeutic target for MPNST.
Usp9X inhibition causes massive reduction in MPNST cell viability. To investigate the poten-
tial role of Usp9X in regulating MPNST cell survival, we first examined the effects of inhibiting Usp9X enzy-
matic activity with the deubiquitinase inhibitor, WP1130, a pharmacological inhibitor of Usp9X known also 
as Degrasyn6, on three NF1 patient-derived MPNST cell lines (ST88-14, T265-2c and 90-8). WP1130 caused 
a concentration-dependent decrease in cell viability after 72 h in all three cell lines, with ST88-14 cells being 
particularly sensitive (Fig. 1a,b,c). In these experiments, we used a concentration range between 0.5 and 2.5 µM, 
established from preliminary results (Suppl. Figure 1b,c). In addition to Usp9X, WP1130 inhibits the enzy-
matic activity of multiple deubiquitinases; thus, to more selectively determine the effects of Usp9X inhibition 
on MPNST cell survival in vitro, we silenced Usp9X gene using siRNA. Suppression of Usp9X was confirmed 
by immunoblotting (Fig. 1g–j). In all three cell lines, Usp9X gene silencing resulted in a significant reduction in 
viable cell numbers after 72 h (Fig. 1d–f). Consistent with the results obtained with pharmacological inhibition of 
Usp9X activity, ST88-14 cells were most strongly affected by Usp9X silencing, with a significant reduction in cell 
viability observed after just 24 h treatment (Fig. 1d). These data support the conclusion that Usp9X is critical for 
the survival of MPNST cells.
Usp9X inhibition depletes Mcl-1. Based on our previously published observation that Usp9X induces 
a decline of Mcl-1 protein levels in GBM cells9,11, we hypothesized that similar effects would be observed in 
MPNST cells. To test this hypothesis, ST88-14 cells were treated with WP1130 at two different concentrations 
(Suppl. Figure 1e) and Mcl-1 levels were assessed by Western blot after 24 and 48 h. Usp9X interference decreased 
endogenous Mcl-1 protein levels at both concentrations after treatment for 48 h (Suppl. Figure 1e). Consistent 
with these results, Usp9X knock-down in ST88-14 cells resulted in decreased Mcl-1 levels at 48 h as well (Suppl. 
Figure 1d).
Figure 1. Usp9X inhibition causes massive reduction in cellular viability in MPNST cell lines. (a–c) ST88-14 
(a), T265-2c (b), 90-8 cells (c) were treated with increasing concentrations of WP1130 for 72 h. Cellular viability 
was determined by CellTiter-Glo assay and the IC50-values were calculated based on a non-linear regression 
analysis. Data are presented as mean and SD, n = 3. (d–f) Usp9X was silenced in ST88-14 (d), T265-2c (e), 
90-8 cells (f) with non-targeting (NT) RNA or siUsp9X for 24, 48 and 72 h. Cellular viability was determined 
by CellTiter-Glo assay and relative cell viability was calculated. Data are presented as mean and SD, n = 3. 
* = 0.0129 *** ≤ 0.001. (g–j) Usp9X knock down was performed in ST88-14, T265-2c and 90-8 cells. Whole-
cell extracts were examined by Western blot for Usp9X. ß-actin Western blot analysis was performed to confirm 
equal protein loading. Bar graphs show protein quantification analyzed through ImageJ. Data are presented as 
mean and SD, n = 3.
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Usp9X knock-down causes MPNST cell death with variable caspase activation and features of 
apoptosis. To determine if Usp9X inhibition induced apoptosis of MPNST cells, we inhibited Usp9X phar-
macologically with WP1130 and silenced it by siRNA, as well, in ST88-14 and T265-2c cell lines and examined 
various biochemical indicators of apoptosis. Usp9X pharmacological inhibition resulted in several features of 
apoptosis (Fig. 2a,b), including a time-dependent decrease in mitochondrial membrane potential (Fig. 2c,d), in 
both cell lines. Consistent with the viability data, ST88-14 cells were more rapidly and strongly affected by Usp9X 
inhibition, than T265-2c cells. As with pharmacological inhibition of Usp9X activity, Usp9X knock-down pro-
duced biochemical features of apoptotic cell death including a significant loss in mitochondrial membrane poten-
tial (Fig. 2a–d). ST88-14 cells consistently showed more dramatic effects after Usp9X interference, compared to 
T265-2c cells (Fig. 2a–d) and caspase 3-like enzymatic activity was more pronounced after Usp9X knock-down 
or WP1130 treatment in ST88-14 cells compared to T265-2c cells (Fig. 2e–g).
Interference with Mcl-1 produces cell death with apoptotic features in MPNST cell lines. Usp9X 
regulates cell survival through both Mcl-1-dependent and –independent processes. To determine if Mcl-1 is a reg-
ulator of MPNST survival, we examined the effects of Mcl-1 knockdown on the three MPNST cell lines. As with 
Usp9X pharmacological inhibition or knock-down, Mcl-1 knock-down resulted in significant cell death in all cell 
lines tested (Fig. 3a–g), most prominently in T265-2c and 90-8 cell lines (Fig. 3d–g). All three cell lines showed 
time-dependent apoptotic features with enhanced DNA fragmentation, annexin V staining (Fig. 3b,f), and loss 
in mitochondrial membrane potential (Fig. 3c,g) with maximal response at 72 h after transfection. T265-2c cells 
were more sensitive to Mcl-1 depletion (Fig. 3d,e), compared to ST88-14 cells (Fig. 3a), with strong features of 
apoptosis (Fig. 3f,g). Suppression of Mcl-1 was confirmed by immunoblotting (Fig. 3h,i). Consistent with these 
results, pharmacological inhibition of Mcl-1 with A-121047712, caused a concentration-dependent decrease in 
cellular viability after 72 h in all tested cell lines (Suppl. Figure 2). These data indicate that in addition to being 
sensitive to Usp9X inhibition, MPNST cell lines are also susceptible to Mcl-1 loss, which appears to activate apop-
tosis, most prominently in the T265-2c cell line.
Caspase-inhibition provides minimal protection from cell death after Usp9X or Mcl-1 deple-
tion. To determine if caspase-dependent apoptosis is the main cell death pathway activated by Usp9X or 
Mcl-1 depletion, we tested the ability of ZVAD, a broad-spectrum caspase inhibitor, to inhibit Usp9X and Mcl-1 
knock-down induced MPNST cell death. Despite producing a complete inhibition of caspase 3-like enzymatic 
activity (Fig. 4c), ZVAD failed to significantly attenuate cell death after Usp9X or Mcl-1knock-down at 72 h in 
ST88-14 (Fig. 4a) or T265-2c cells (Fig. 4b), indicating that other caspase-independent death pathways are likely 
activated in parallel with apoptosis following Usp9X or Mcl-1 inhibition.
Usp9X inhibition causes ER stress in MPNST cell lines. Interestingly, both Usp9X pharmacological 
inhibition and silencing in MPNST cells elicited a significant increase in ATF3, a typical marker of ER-stress 
(Fig. 5a,b) and in the pro-apoptotic BH3-only protein Noxa (Fig. 5a,b). The protein expression level of a second 
ER stress marker, ATF4, was similarly increased in ST88-14 cells after Usp9X disruption (data not shown). Given 
that ATF3 and ATF4 are downstream regulators of the ER-stress response7 and are capable of activating Noxa7, we 
hypothesized that cell death induced by Usp9X inhibition may in part be mediated through an ER stress response.
Ultrastructural examination of MPNST cells following Usp9X inhibition reveals evidence of 
paraptosis. We used transmission electron microscopy (TEM) to determine if there was ultrastructural evi-
dence of ER stress in MPNST cells following Usp9X inhibition. T265-2c cells were treated with vehicle or 2.5 µM 
WP1130 for 24 h and processed for TEM. Vehicle treated cells showed intact organelles and normal ER structure 
(Fig. 5c–e). In contrast, WP1130 treated T265-2c cells exhibited significant morphological changes including 
reduced cell size and altered cell shape (Fig. 5f). In addition, following WP1130 treatment T265-2c cells exhibited 
numerous small and large clear cytoplasmic vacuoles (Fig. 5f). The typical ultrastructural features of apopto-
sis, e.g. chromatin condensation and margination and membrane blebbing were only rarely observed in treated 
cells (Fig. 5f–h). Striking changes in ER and mitochondrial ultrastructure previously described in paraptotic cell 
death13,14 were seen following WP1130 treatment of T265-2c cells. Compared with vehicle treated cells, WP1130 
exposed cells showed significant swelling and disruption of normal ER structure with dramatic expansion of the 
ER lumina (Fig. 5d and g). Similarly, in contrast with normal appearing mitochondria in vehicle treated cells, 
numerous mitochondria in the WP1130 treated cells were markedly enlarged, edematous, disorganized and frag-
mented (Fig. 5e and h). Taken together, these results suggest that WP1130 induces paraptosis13 in T265-2c cells.
WP1130 inhibits MPNST tumor growth in vivo. To assess the potential efficacy of Usp9X inhibition 
in treating MPNSTs in vivo, we tested WP1130 in a heterotopic xenograft MPNST model. ST88-14 cells were 
implanted subcutaneously and animals were divided into three groups receiving either vehicle or two different 
concentrations of WP1130 (12.5 and 25 mg/kg intraperitoneally) (Fig. 6 and Suppl. Figure 3). In our initial in vivo 
experiment, treatment was initiated eight days after implantation and injections were given three times/week for 
four weeks (Fig. 6a–f). WP1130 at 25 mg/kg per dose produced a statistically significant growth reduction with 
partial regression of tumors compared to vehicle treated controls (Fig. 6a). The day after the last injection, tumors 
were resected and the tumor volume and weight measured. WP1130 produced a significant decrease in tumor 
volume at both concentrations (Fig. 6b) and a statistically significant decrease in tumor weight in the 25 mg/kg 
dose group (Fig. 6c and d). The regression of the tumors’ size suggested that this treatment not only attenuated 
tumor growth but induced tumor cell death. Histopathological analysis of the resected tumors in the vehicle 
treated control group showed densely cellular, highly pleomorphic tumors with brisk mitotic activity (Fig. 6e). 
In contrast, mice treated with WP1130 showed tumors with reduced cellularity and mitotic activity, multi-focal 
necrotic areas and the presence of scattered apoptotic nuclei throughout the tumors at both concentrations 
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Figure 2. Usp9X inhibition induces cell death with features of apoptosis and loss of membrane potential in 
MPNST cell lines. (a–d) ST88-14 (a,c) and T265-2c cells (b,d) were treated with WP1130 at the concentration 
of 2.5 µM, or transfected either with non-targeting (NT)-siRNA or Usp9X-siRNA. (a,b) Staining for annexin V/
Propidium Iodide was performed prior to flow cytometric analysis. Representative flow plots are shown. N = 3. 
(c,d) Cells were stained with Mitochondrial Membrane Potential Assay Kit (TMRE), then flow cytometric 
analysis was performed. N = 3. (e,f) ST88-14 cells were treated with WP1130 at the concentration of 2.5 µM 
(e) or transfected either with non-targeting (n.t.)-siRNA or Usp9X-siRNA (f), then caspase 3-like enzymatic 
activity was measured at different time points. Column: mean. Error bar: SD, n = 3. * = 0.0209 ** = 0.0026 
*** ≤ 0.001. (g) T265-2c cells were treated with WP1130 at the concentration of 2.5 µM prior to caspase 3-like 
activity measurement at different time points.
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(Fig. 6f). WP1130 inhibition of Usp9X leads to the inhibition of Usp9X function and thus, an expected decrease 
in the levels of Usp9X substrates15. To verify the in vivo effectiveness of WP1130 treatment, we tested the protein 
levels of Mcl-1 in xenografts from vehicle and WP1130 treated mice and found a significant reduction in Mcl-1 
Figure 3. Mcl-1 knock-down causes massive reduction in cellular viability, cell death with features of apoptosis 
and loss of membrane potential in MPNST cell lines. (a,d,e) ST88-14 (a) 90-8 (d), T265-2c (e) cells were 
transfected either with non-targeting (NT)-siRNA or Mcl-1-siRNA for 24, 48 and 72 h. Cellular viability was 
determined by CellTiter-Glo assay and relative cell viability was calculated. Data are presented as mean and SD, 
n = 3. *(a) = 0.0161, *(d) = 0.0015, *(e) = 0.0168, *** ≤ 0.001 (b,f) Staining for annexin V/Propidium Iodide 
was performed prior to flow cytometric analysis. Representative flow plots are shown. N = 3. (c,g) Staining 
for Mitochondrial Membrane Potential Assay Kit (TMRE) was performed prior to flow cytometric analysis. 
Representative flow plots are shown. N = 3. (h,i) Knock down of Mcl-1 was confirmed in ST88-14 cells (h) and 
T265-2c cells (i) by Western blot analysis. ß-actin was used to ensure equal loading.
www.nature.com/scientificreports/
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levels in vivo (Fig. 6g). To extend these findings, we performed a second in vivo experiment in which we allowed 
the tumors to grow to a significant size before initiating WP1130 therapy to better model the human situation. 
Therefore, we implanted ST88-14 cells and waited one month before initiating daily injections of WP1130 for five 
days per week for two weeks (Suppl. Figure 3). WP1130 treatment resulted in a significant attenuation in tumor 
growth when compared to the vehicle treated group (Suppl. Figure 3a). Histopathological analysis of the resected 
tumors showed features similar to those observed in the initial in vivo study. WP1130 reduced cellularity and 
induced cell death, with multiple areas of necrosis and presence of frequent apoptotic nuclei, at both concentra-
tions (Suppl. Figure 3c), compared to the control group (Suppl. Figure 3b). WP1130 treatment also resulted in a 
marked increase in cleaved caspase 3 immunoreactivity and TUNEL labeling compared to tumors of the vehicle 
group (Suppl. Figure 4a–d). To preliminarily assess potential in vivo toxic effects of WP1130, we performed body 
weight measurements on vehicle and WP1130 treated animals throughout the experiment and found no differ-
ences between the three groups (data not shown) suggesting that WP1130 does not have obvious toxic effects. 
These results are consistent with several previous in vivo studies of WP11306,16,17.
Discussion
The goal of this study was to determine if Usp9X and/or Mcl-1 play(s) a role in MPNST cell survival and thus, 
serve as potential therapeutic targets for MPNST treatment. Usp9X is a deubiquitinating enzyme18 that plays a 
role in regulating protein degradation by modulation of ubiquitin conjugation to its targets and thereby con-
trolling their proteasomal turnover19. It is well established that Usp9X plays a pivotal role in various malignant 
Figure 4. Caspase-dependent apoptosis is not the exclusive MPNST cell death pathway activated after Usp9X 
and Mcl-1 knock down in vitro. (a,b) ST88-14 (a) and T265-2c (b) cells were transfected with non-targeting 
(NT)-siRNA with or without z-VAD as controls, or Usp9X-siRNA, or Mcl-1-siRNA for 72 h. Cellular viability 
was determined by CellTiter-Glo assay and relative cell viability was calculated. Data are presented as mean 
and SD, n = 3. (c) Caspase-3 like activity was measured at 24 h after treatments in ST88-14 cell line. Data are 
presented as mean and SD, n = 3.
www.nature.com/scientificreports/
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tumors affecting the nervous system, including GBM6,11,20. Mechanistically, Usp9X exerts its effects on cell sur-
vival at least in part by controlling the levels of anti-apoptotic Bcl-2 family members, including Mcl-1, or inhibitor 
of apoptosis proteins, such as XIAP8. Interference with Usp9X results in degradation of these survival promoting 
proteins8,19. Studies related to other malignancies, such as pancreatic cancer, demonstrated that Usp9X is neces-
sary to drive tumor growth by inhibition of cell death21. However, it should be noted that the effects of Usp9X 
on tumors are likely to be context dependent since at least one study, involving a transgenic mouse model of 
pancreatic cancer, suggested that Usp9X played a tumor suppressive role22. Such observations do not void Usp9X 
as a cancer therapeutic target, but they remind us that some proteins have tumor type-specific biological roles 
that must be determined experimentally before advancing to human trials for any given cancer type. There might 
also be “context” dependent and functional differences between tumor initiation and the propagation of estab-
lished malignancies. This is the first study that we are aware of examining the potential role of Usp9X in MPNST 
survival. Given that anti-apoptotic Bcl-2 family members are important cell death mediators in the context of 
Figure 5. Usp9X inhibition causes Noxa increase and ER stress in MPNST cell lines. Ultrastructural analysis 
shows features of paraptosis. (a,b) ST88-14 cells were transfected for 24 h with either non-targeting (NT)-siRNA 
or Usp9X-siRNA (a) or treated with WP1130 at the concentration of 1.25 and 2.5 µM (b). Whole cell extracts 
were collected prior to Western blot analysis for ATF3, Noxa and ß-actin. Numbers shows protein quantification 
analyzed through ImageJ. N = 3. (c–e) Ultrastructural appearance of untreated control cells using TEM. (f–h) 
After treatment with WP1130 at the concentration of 2.5 µM (f,g,h) T265-2c cells showed extensive cytosolic 
vacuolization (f, red arrows) and swelling of ER (g, red arrowheads) and mitochondria (h, red arrows).
www.nature.com/scientificreports/
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MPNST and that Mcl-1 is a central regulator of apoptosis in sarcomas10, a pivotal role of Usp9X as a potential 
therapeutic target in MPNSTs appears likely.
The current study offers evidence to support the hypothesis that targeting Usp9X might significantly impact 
MPNST viability. In our report, by both pharmacological and genetic targeting of Usp9X in vitro, we detected not 
only inhibition of cell growth, but also massive cell death. WP1130 inhibits Usp9X deubiquitinase activity as well 
as that of several other deubiquitinases such as Usp5, Usp14, and UCH3723. First, we showed that WP1130, in a 
concentration- and time-dependent manner, decreases the viability of three different human NF1 patient-derived 
MPNST cell lines, ST88-14, T265-2c and 90-8. To determine the specific role of Usp9X in MPNST cell survival, 
we silenced Usp9X by siRNA. The selective knock-down of Usp9X caused a significant reduction in cell via-
bility in all three MPNST cell lines tested. Both pharmacological inhibition and Usp9X knock down, caused 
time-dependent MPNST cell death with some features of apoptosis, including loss in mitochondrial membrane 
potential. However, the extent of caspase-3 enzymatic activity varied between cell lines being most robust in 
ST88-14 cells with minimal caspase activation observed in T265-2c cells. Thus, the extent of caspase-3 enzymatic 
Figure 6. Treatment with WP1130 reduces tumor size in a mouse MPNST model generated by subcutaneous 
injection of ST88-14 cell line. (a) Tumor growth curves showing the increase in tumor size for each treatment 
group. Data are presented as mean and SEM. Asterisks shown only for 25 mg/Kg dose, compared to control 
group. Asterisks values, from left to right: 0.0413, 0.0321, 0.0409, 0.0479 and 0.0162. (b) Quantification of the 
tumors volume among different treatment groups 35 days after tumor implantation. * = 0.0202, *1 = 0.0198. 
(c) Quantification of the tumors weight among different treatment groups 35 days after tumor implantation. 
* = 0.0458. (d) Representative photographs of the tumors. (e,f) Representative photomicrographs showing 
the histological morphology (H & E staining) of tumors from mice receiving either vehicle or WP1130 at the 
concentration of 12.5 mg/kg. Arrows indicate mitotic figures. Scale bar, 50 µm. (g) Whole tissue extracts from 
vehicle and 25 mg/kg WP1130 treated mice were collected prior to Western blot analysis for Mcl-1 and ß-actin 
served as loading control. Numbers shows protein quantification analyzed through ImageJ. N = 3.
www.nature.com/scientificreports/
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activity after WP1130 in our cell lines seems to be dependent on cell-specific factors that remain to be deter-
mined. Interestingly, treatment of MPNST cell lines with a broad caspase inhibitor failed to significantly attenuate 
cell death after Usp9X knock-down suggesting that caspase-independent death pathways are also activated. In 
all MPNST cell lines tested, but most prominently in the T265-2c cell line, Mcl-1 knock-down-induced death 
displayed features of apoptosis such as increased annexin V staining and decreased mitochondrial membrane 
potential but, as in Usp9X knock-down cells, broad caspase inhibition did not protect MPNST cells from Mcl-1 
knock-down-induced death. We also tested a novel small-molecule inhibitor of Mcl-1, A1210477, since these 
compounds are currently in preparation for human clinical application, and our results suggest that this com-
pound exerts anti-proliferative activity against MPNST cells. From these data, we conclude that Usp9X and Mcl-1 
are central cell death regulators in MPNSTs and that although caspases may be activated following their inhibi-
tion, caspase-independent pathways contribute significantly to the MPNST cell death promoting effects of Usp9X 
and Mcl-1 inhibition in vitro.
The mechanism by which Usp9X interference induced massive reduction of viability in MPNST cell lines 
appears to be multiple. Biochemical analysis showed that Usp9X inhibition caused an ER stress response with 
an increase of ATF3 and ATF4, two markers of ER stress, followed by an increase in pro-apoptotic Noxa and a 
subsequent decrease in Mcl-1 protein levels. Similar to our in vitro observations, ST88-14 xenografts following 
treatment with WP1130 showed a significant reduction in Mcl-1 protein levels in vivo.
According to previous publications24, upon ER stress, the ER lumen is remarkably enlarged in cells, which 
can be detected by electron microscopic examination. Ultrastructural examination of MPNST cells following 
WP1130 treatment showed features of ER stress and paraptosis, a type of caspase-independent cell death asso-
ciated with ER damage. These results suggest for the first time a relation between Usp9X and ER stress in the 
context of MPNST. In addition, we noted an increase in pro-apoptotic Noxa, which is known to be regulated 
by ATF3 and ATF425,26 and which preceded the down-regulation of Mcl-17. Although a relationship between 
Noxa induction and Usp9X inhibition has not been described before in MPNST cells, these results suggest that 
Noxa might be implicated in the death produced by Usp9X inhibition. As explained above, we found a decline 
in Mcl-1 levels upon Usp9X inhibition, which is in keeping with earlier findings in other model systems7,18,27,28. 
However, our study demonstrated that Noxa up-regulation precedes Mcl-1 down-regulation, suggesting that the 
Noxa increase is proximal of Mcl-1 with respect to cell death induction. Given that Noxa is an inhibitor of Mcl-1 
and has been known to stimulate Mcl-1 mediated proteasomal degradation, Usp9X inhibition might in part lead 
to a reduction of Mcl-1 levels through Noxa mediated destabilization of Mcl-1. However, taking this speculation 
aside, at the minimum, increased Noxa levels will facilitate release of BAK and BIM from Mcl-1, thereby driving 
BAX/BAK mediated intrinsic apoptosis.
In seeking to identify others forms of cell death produced by Usp9X inhibition in MPNST cells, TEM analysis 
showed morphological features of paraptosis with extensive cytoplasmic vacuolization, swelling of ER and mito-
chondria and only minimal features of apoptosis13,14. To the best of our knowledge, presence of paraptosis has 
never been described before in relation to MPNSTs or in the context of Usp9X inhibition.
To determine if Usp9X inhibition has therapeutic potential in vivo, we tested WP1130 in a heterotopic 
MPNST xenograft model. WP1130 treatment resulted in a statistically significant growth reduction and partial 
regression of tumors. These results suggest that WP1130 might be useful for MPNST treatment. Our findings 
are in keeping with the results of others that have observed anti-cancer effects of WP1130 in various xenograft 
model systems6,16,17. While we found single agent efficacy with Usp9X and Mcl-1 inhibitors in MPSNT model 
systems, it is tempting to speculate as to whether these effects may be further enhanced by drug combination 
therapies. The literature suggests that in other tumor entities, including GBM, the efficacy of Mcl-1 inhibitors 
is dramatically increased in the presence of other drug compounds11,29. Similar results have been found with 
regards to Usp9X inhibition15. For instance, Bcl-2/Bcl-xL- inhibition coupled with the inhibitor WP1130 showed 
synergistic anti-cancer effects in several preclinical model systems18,30. In conclusion, our study demonstrates 
that MPNST cell lines are susceptible to both Usp9X and Mcl-1 loss which appears to activate both apoptotic and 
caspase-independent death pathways, such as paraptosis.
Materials and Methods
Ethics statement. All procedures were in accordance with Animal Welfare Regulations and approved by 
the Institutional Animal Care and Use Committee at the Columbia University Irving Medical Center. The study 
was reviewed and approved by the institutional review board at the Columbia University Irving Medical Center.
Reagents. Primary antibodies were obtained from the following sources: Usp9X (Cell Signaling, Danvers, 
MA #5751), Mcl-1 (Cell Signaling, Danvers, MA #5453), Noxa (Calbiochem, San Diego, CA #OP180), ATF4 (Cell 
Signaling, Danvers, MA #11815), ATF3 (Novus Biologicals, Littleton, CO #NBP1-85816), β-actin (Sigma, St. 
Louis, MO #A5316). Secondary antibodies were HRP-conjugated goat anti-rabbit (Thermo Scientific, Waltham, 
MA #31460) and goat anti-mouse (Thermo Scientific, Waltham, MA #31430). Degrasyn [WP1130] was obtained 
from Selleckchem (Houston, TX #S2243). A-1210477 was purchased from APExBIO (Houston, TX #B6011). 
Tunicamycin [TUN] and Staurosporine [STS] were purchased from Sigma (St. Louis, MO; TUN #T7765, STS 
#S5921).
Cell culture. The human NF1-associated MPNST lines used in this study are: T265-2c cells, ST88-14 cells 
and 90-8 cells, obtained and maintained as described31,32. Morphology and doubling times of cells were routinely 
assessed, according to the guidelines contained in the ATCC Technical Bulletin 8. The identity of cells was verified 
by short tandem repeat analyses. The short tandem repeat profile of each sporadic MPNST cell line was deter-
mined by examining 15 markers standardly used by the American Type Culture Collection and the amelogenin 
locus (included to verify the sex of the patient from which the tumor was derived) with an AmpFLSTR system 
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(Applied Biosystems; Foster City, CA). Cells were regularly tested for Mycoplasma infection, as well. Cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Corning, Manassas, VA), containing 1% penicillin/
streptomycin (Invitrogen, Carlsbad, CA), 1% L-glutamine (Sigma, St. Louis, MO), and 10% fetal bovine serum 
(FBS;Hyclone, Logan, UT) and incubated at 37 °C in a humidified 5% CO2, 95% air atmosphere. For cell viabil-
ity studies, cells were plated on uncoated 96 well plates at a density of 4,000/well. For caspase 3-like enzymatic 
activity assays, on uncoated 48 well plates at a density of 20,000/well. For flow analyses and lysate collection, on 
uncoated 12 well plates at a density of 50,000/well, and in 100 mm dishes at a density of 106 cells/dish. Cultures 
were used in experiments 24 hours post-plating unless stated otherwise. Drug treatments were performed in 
media supplemented with 2% FBS.
RNAi. SignalSilence Usp9X siRNA I #6308 was purchased from Cell Signaling. Non-targeting siRNA-pool 
(ON-TARGETplus Non-targeting Pool, # D-001810-10-05) and Mcl-1 (SMARTpool: ON-TARGETplus Mcl-1 
siRNA, L-004501-00-0005) were purchased from Thermo Fisher Scientific (Pittsburgh, PA). MPNST cell lines 
were transfected as previously described33. Cells were plated on 12 wells plates. After 24 hours, they have been 
incubated with the formed complexes of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and the respective 
siRNA (12-well condition) in DMEM without FBS and antibiotics. The day after, FBS was added to a total con-
centration of 2%.
Cell viability and caspase cleavage assays. Cellular proliferation was measured using CellTiter-Glo 
assays (Promega, Madison, WI), according to the manufacturer’s instructions. Briefly, cells were plated in 96-well 
plates. After treatments, 100 μl of CellTiter-Glo Reagent was added to each well containing 100 μl medium and 
cells. Cell lysis was induced by shaking for 2 min on an orbital shaker. Then cells were incubated for 10 min at RT 
for stabilization of the signal prior to measuring luminescence. Luminescence was measured using a plate reader 
(SpectraMax i3x multi-mode detection platform, Molecular Devices). Caspase activation was assessed with an 
in vitro caspase-3 like cleavage assay utilizing the chemical substrate DEVD-7-amino-4-methylcoumarin (AMC) 
(Enzo Life Sciences, Framingdale, NY #ALX-260-031). Assay was performed as previously described34.
Measurement of apoptosis and mitochondrial membrane potential. For annexin V/propidium 
iodide (PI) staining the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, USA) was used according 
to the manufacturer’s instructions. TMRE staining was performed using CellSimple™ Mitochondrial Membrane 
Potential Assay Kit (II) (Cell Signaling #45898), in accordance with the manufacturer instructions. Fluorescence 
was measured using a BD FACSCalibur flow cytometer. The data were analyzed with the FlowJo software (version 
8.7.1; Tree Star, Ashland, OR, USA).
Western blotting. Whole cell lysates were prepared by removing the media and lysing cells directly in 
Laemmli buffer, containing 5% 2-Mercaptoethanol (Bio-Rad #161-0710), 95% 2x Laemmli Sample Buffer 
(Bio-Rad #161-0737) and protease and phosphatase inhibitor cocktail (Thermo Scientific #1861281). Lysates were 
stored at −80 °C. Whole tumor lysates were prepared by lysing the tissues directly in RIPA buffer (Thermo Fisher 
#89900) with the addition of protease and phosphatase inhibitor cocktail (Thermo Scientific #1861281). Tumors 
were mechanically disaggregated followed by sonication. Insoluble material was removed by centrifugation at 
12,000 r.p.m., and the supernatant was collected for protein quantification. Lysates were immediately stored at 
−80 °C.
Western blots were performed as described previously35. All primary antibodies were diluted to a final con-
centration of 1:500, except β-actin (1:8000). Secondary antibodies conjugated with horseradish-peroxidase were 
used at a dilution of 1:5000. For immunodetection, the Pierce ECL Western blotting substrate was utilized (Pierce 
ECL; Thermo Scientific, Waltham, MA). Membranes were developed using Azure c-300 gel doc & western blot 
Imaging (Azure Biosystem). Quantification of Western blot bands was performed with the open source image 
processing program ImageJ.
Transmission Electron Microscopy. Cells were fixed with 2.5% glutaraldehyde in 0.1 M Sorenson’s buffer 
(PH 7.2) for at least one hour, then postfixed with 1% OsO4 also in Sorenson’s buffer for one hour. After dehy-
dration cells were embedded in a mixture of Lx-112 (Ladd Research Industries, Inc.) and Embed-812 (EMS, 
Fortwashington, PA). Thin sections (60 nm) were cut on the MT-Power-Trome XL ultramicrotome. Sections were 
stained with uranyl acetate and lead citrate and examined under a JEOL JEM-1200 EXII electron microscope. 
Images were taken on an ORCA-HR digital camera (Hamamatsu) and recorded with the AMT Image Capture 
Engine.
Subcutaneous xenograft model. 7 × 106 ST88-14 cells suspended 1:1 in Matrigel Matrix (Corning Inc., 
Corning, NY, USA) were implanted subcutaneously into one flank (first experiment) and into both flanks (second 
experiment) of 6–8 week-old SCID SHO mice as previously described18. 4 mice per experimental group were 
used. Vehicle or drug was injected intraperitoneally 3 times each week for 4 weeks during the first in vivo study, 
and for five of seven days, from Monday to Friday, for 2 weeks during the second in vivo experiment. For intra-
peritoneal application WP1130 were dissolved in a solution of 80% Cremophor EL (SIGMA, St. Louis, MO) and 
20% Ethanol (Pharmco-Aaper, Brookfield, CT) (v/v), diluted 1:1 in sterile PBS.
Histological analysis. Subcutaneous tumors and samples from organs were removed from SCID SHO mice 
and fixed for at least 24 h in 4% PBS-buffered formalin. Then tissues were embedded in paraffin and 4 μm thick 
sections were cut prior to staining with hematoxylin and eosin, TUNEL (Click-iT™ TUNEL Colorimetric IHC 
Detection Kit, Thermo Fisher #C10625) or cleaved caspase 3 (Cell Signaling #9661). Photomicrographs were 
taken at X40 and X60 magnification.
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Statistics. All data points represent mean ± S.D. All experiments were repeated at least 3 times unless stated 
otherwise. Representative data is shown. Statistical significance was determined by one-way ANOVA test for 
multiple comparisons and student’s t-test for two groups using Graphpad Prism 6 software. A p-value ≤ 0.05 was 
considered significant.
Data Availability Statement
all the data are available upon request.
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